Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XanaHES: A Phase I, Single Blinded, Central Reader Blinded, Placebo-Controlled, Dose Escalation Study of Xanamem™ to Assess Safety and Tolerability in Healthy Elderly Subjects

NCT03830762 is registered in ClinicalTrials.gov with Actinogen Medical as lead sponsor.

NCT NCT03830762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03830762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XanaHES: A Phase I, Single Blinded, Central Reader Blinded, Placebo-Controlled, Dose Escalation Study of Xanamem™ to Assess Safety and Tolerability in Healthy Elderly Subjects
Lead sponsor
Actinogen Medical
Phase
Phase 1
Overall status
Completed
Start date
January 21, 2019
Completion date
January 7, 2020
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system, cerebrospinal fluid, cognitive function, cortisol, electrocardiography, healthy ageing, peripheral neuropathy, safety, small fibre neuropathy